© 2024 Iowa Public Radio
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Iowan Participating In Pfizer COVID-19 Vaccine Trial Reflects On Ongoing Experience

For now, Pfizer's world headquarters remains in New York. But a deal for AstraZeneca could turn Pfizer British.
Mark Lennihan
/
AP
More than 40,000 people are participating in the clinical trial for Pfizer's experimental COVID-19 vaccine.

Cedar Rapids City Council Member Ashley Vanorny talks with IPR's Clay Masters about her experience with the Pfizer COVID-19 vaccine testing trial through the University of Iowa.

Pfizer's experimental COVID-19 vaccine appears to be working. On Monday it was reported that the vaccine was found to be more than 90 percent effective, according to clinical results released by the company.

More than 40,000 people are taking part in the clinical study and one of those participants is Ashley Vanorny who works in healthcare administration industry and serves on the Cedar Rapids City Council. She's among 270 people taking part in the University of Iowa's portion of the study. University of Iowa experts say it could still be awhile before the vaccine is widely distributed.

Clay Masters is the senior politics reporter for MPR News.